Premera Blue Cross and Express Scripts Agree to Contract Extension

Go back to Premera Blue Cross and Express Scripts Agree to Contract Extension

Express Scripts (ESRX), Imprimis Pharma (IMMY) to Partner on Low-Cost Alternative to Turing's Daraprim

December 1, 2015 6:24 AM UTC

Express Scripts (Nasdaq: ESRX) announced it will partner with Imprimis Pharmaceuticals (Nasdaq: IMMY) to drive access to a low-cost alternative to Daraprim (pyrimethamine), a drug for the treatment of toxoplasmosis that has been recently priced out of reach for people with HIV, pregnant women and others with weakened immune systems.

Imprimis is offering a compounded oral formulation of pyrimethamine and leucovorin (a form of folic acid) for $1 per capsule for people whose pharmacy benefit is managed by Express Scripts. While the 62-year-old Daraprim was priced $13.50 per pill... More